Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study, leading the biotech to reaffirm that the therapy is no longer a priority. The drug in question, formerly ...
Cryptopolitan on MSN
This promising anti-aging drugs just failed its human test
One of the most studied lifespan-extending drugs in animals has just failed its test on humans in a 13-week clinical trial co ...
Patients dosed with an experimental Skye Bioscience obesity drug did not lose enough weight to meet the goals of a mid-stage study, dealing a setback to the biotech’s bid to revive a class of ...
Sept 24 (Reuters) - Harmony Biosciences (HRMY.O), opens new tab said on Wednesday its experimental drug for a rare genetic disorder failed to meet the main goal in a late-stage trial, sending its ...
AstraZeneca’s gefurulimab met its primary endpoint, but has not managed to best the efficacy demonstrated by its rival therapies in a late-stage generalised myasthenia gravis (gMG) trial. In the Phase ...
Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis. The Johnson & Johnson-partnered asset, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results